AMAG Pharmaceuticals is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of atherapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The Company has two commercial products: Feraheme® (ferumoxytol) Injection for Intravenous (IV) Use and GastroMARK® (ferumoxsil).

Contact Information

100 Hayden Ave
Lexington, MA 02421

tel: (617) 498–3300
fax: (617) 499-3361


Investor Relations

e-mail: contactus@amagpharma.com


Exchange: NASDAQ
Industry: Diagnostic Substances
Market Cap: $664M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.